BioDelivery Sciences International, a specialty pharmaceutical company dedicated to serious and complex chronic conditions, has appointed Jeffrey A. Bailey, as interim Chief Executive Officer and a member of the Company’s Board of Directors. Mr. Bailey succeeds Herm Cukier as CEO.

Mr. Bailey has led both public and private healthcare companies where he has leveraged his leadership experiences in commercial, supply chain and business development, as well as in-licensing and transactions. His experience includes a 20+ year career at Johnson & Johnson/Janssen Pharmaceutica as well as a tenure as Operating Unit President at Novartis Pharmaceuticals, Chief Commercial Officer at King Pharmaceuticals, Chief Operating Officer at Fougera Pharmaceuticals, and Chairman and CEO of Neurovance. Mr. Bailey also served as President and CEO of Lantheus Medical Imaging, Inc, taking the company public in 2015. Most recently, he was the CEO of IlluminOss Medical, Inc, which was acquired last month.

“On behalf of the Board and our entire Company, I am excited that Jeff Bailey has agreed to serve as Interim CEO,” stated Peter Greenleaf, Chairman of the Board of Directors of BDSI. “The Board thanks Herm Cukier for his leadership during a transformative time in the Company’s history, and we wish him the best in the future.”

“Jeff Bailey has a terrific track record of leading organizations and delivering shareholder value,” stated Kevin Kotler, Chair of the Nominating & Corporate Governance Committee and founder of Broadfin Capital.  “We look forward to his help in refining and driving our long-term strategic plan.”